Testing the Addition of KRT-232 (AMG 232) to Usual Chemotherapy for Relapsed Multiple Myeloma

NCT03031730 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

35

Enrollment

NIH

Sponsor class

Stopped Inadequate accrual rate

Conditions

Plasmacytoma
Recurrent Multiple Myeloma
Refractory Multiple Myeloma

Interventions

PROCEDURE: Biospecimen Collection
PROCEDURE: Bone Marrow Aspiration and Biopsy
DRUG: Carfilzomib
DRUG: Dexamethasone
DRUG: Dexamethasone Sodium Phosphate
PROCEDURE: Echocardiography
DRUG: Lenalidomide
DRUG: Navtemadlin

Sponsor

National Cancer Institute (NCI)